Wells Fargo’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-793
| Closed | -$294 | – | 7458 |
|
|
2025
Q1 | $294 | Hold |
793
| – | – | ﹤0.01% | 6307 |
|
|
2024
Q4 | $567 | Buy |
793
+215
| +37% | +$223 | ﹤0.01% | 6304 |
|
|
2024
Q3 | $648 | Hold |
578
| – | – | ﹤0.01% | 6157 |
|
|
2024
Q2 | $630 | Sell |
578
-304
| -34% | -$342 | ﹤0.01% | 6128 |
|
|
2024
Q1 | $1.12K | Sell |
882
-420
| -32% | -$555 | ﹤0.01% | 6125 |
|
|
2023
Q4 | $1.81K | Buy |
1,302
+20
| +2% | +$27 | ﹤0.01% | 6117 |
|
|
2023
Q3 | $1.8K | Buy |
1,282
+7
| +0.5% | +$11 | ﹤0.01% | 6105 |
|
|
2023
Q2 | $2.35K | Buy |
1,275
+16
| +1% | +$37 | ﹤0.01% | 6190 |
|
|
2023
Q1 | $3.06K | Sell |
1,259
-2,633
| -68% | -$3.92K | ﹤0.01% | 6163 |
|
|
2022
Q4 | $5.57K | Buy |
3,892
+2,436
| +167% | +$4.75K | ﹤0.01% | 5736 |
|
|
2022
Q3 | $3K | Buy |
1,456
+371
| +34% | +$896 | ﹤0.01% | 6095 |
|
|
2022
Q2 | $2K | Buy |
1,085
+25
| +2% | +$62 | ﹤0.01% | 6396 |
|
|
2022
Q1 | $4K | Hold |
1,060
| – | – | ﹤0.01% | 6545 |
|
|
2021
Q4 | $4K | Buy |
1,060
+1
| +0.1% | +$3 | ﹤0.01% | 6773 |
|
|
2021
Q3 | $4K | Sell |
1,059
-15
| -1% | -$50 | ﹤0.01% | 6461 |
|
|
2021
Q2 | $4K | Sell |
1,074
-22,228
| -95% | -$69.9K | ﹤0.01% | 6418 |
|
|
2021
Q1 | $81K | Sell |
23,302
-92,848
| -80% | -$289K | ﹤0.01% | 5579 |
|
|
2020
Q4 | $293K | Sell |
116,150
-60,018
| -34% | -$131K | ﹤0.01% | 4887 |
|
|
2020
Q3 | $371K | Sell |
176,168
-31,287
| -15% | -$74.3K | ﹤0.01% | 4565 |
|
|
2020
Q2 | $465K | Sell |
207,455
-69,709
| -25% | -$179K | ﹤0.01% | 4382 |
|
|
2020
Q1 | $701K | Sell |
277,164
-305
| -0.1% | -$749 | ﹤0.01% | 3786 |
|
|
2019
Q4 | $730K | Buy |
277,469
+377
| +0.1% | +$1.13K | ﹤0.01% | 4079 |
|
|
2019
Q3 | $997K | Sell |
277,092
-121,959
| -31% | -$432K | ﹤0.01% | 3835 |
|
|
2019
Q2 | $1.34M | Sell |
399,051
-39,332
| -9% | -$139K | ﹤0.01% | 3662 |
|
|
2019
Q1 | $1.2M | Buy |
438,383
+68,533
| +19% | +$224K | ﹤0.01% | 3742 |
|
|
2018
Q4 | $1.03M | Buy |
369,850
+5,238
| +1% | +$17.2K | ﹤0.01% | 3831 |
|
|
2018
Q3 | $1.5M | Sell |
364,612
-1,752
| -0.5% | -$7.96K | ﹤0.01% | 3653 |
|
|
2018
Q2 | $1.9M | Buy |
366,364
+63,747
| +21% | +$388K | ﹤0.01% | 3489 |
|
|
2018
Q1 | $1.66M | Sell |
302,617
-9,209
| -3% | -$64.9K | ﹤0.01% | 3523 |
|
|
2017
Q4 | $2.54M | Buy |
311,826
+9,754
| +3% | +$93.2K | ﹤0.01% | 3177 |
|
|
2017
Q3 | $3.16M | Buy |
302,072
+106,342
| +54% | +$1.18M | ﹤0.01% | 2911 |
|
|
2017
Q2 | $2.16M | Sell |
195,730
-117,083
| -37% | -$1.09M | ﹤0.01% | 3159 |
|
|
2017
Q1 | $2.62M | Buy |
312,813
+101,264
| +48% | +$713K | ﹤0.01% | 2985 |
|
|
2016
Q4 | $1.47M | Buy |
211,549
+197,571
| +1,413% | +$1.26M | ﹤0.01% | 3408 |
|
|
2016
Q3 | $71K | Hold |
13,978
| – | – | ﹤0.01% | 5117 |
|
|
2016
Q2 | $83K | Sell |
13,978
-6,038
| -30% | -$33.5K | ﹤0.01% | 4939 |
|
|
2016
Q1 | $91K | Sell |
20,016
-5,450
| -21% | -$24.3K | ﹤0.01% | 4901 |
|
|
2015
Q4 | $114K | Buy |
25,466
+24,885
| +4,283% | +$105K | ﹤0.01% | 4828 |
|
|
2015
Q3 | $2K | Sell |
581
-5,259
| -90% | -$16K | ﹤0.01% | 6009 |
|
|
2015
Q2 | $18K | Buy |
5,840
+2,909
| +99% | +$8.18K | ﹤0.01% | 5639 |
|
|
2015
Q1 | $8K | Buy |
2,931
+61
| +2% | +$200 | ﹤0.01% | 5711 |
|
|
2014
Q4 | $13K | Sell |
2,870
-487
| -15% | -$2.32K | ﹤0.01% | 5531 |
|
|
2014
Q3 | $18K | Sell |
3,357
-1,039
| -24% | -$5.54K | ﹤0.01% | 5358 |
|
|
2014
Q2 | $24K | Sell |
4,396
-20,295
| -82% | -$87.8K | ﹤0.01% | 5299 |
|
|
2014
Q1 | $103K | Buy |
24,691
+21,132
| +594% | +$72.4K | ﹤0.01% | 4638 |
|
|
2013
Q4 | $11K | Buy |
3,559
+2,048
| +136% | +$5.08K | ﹤0.01% | 5177 |
|
|
2013
Q3 | $3K | Sell |
1,511
-744
| -33% | -$1.76K | ﹤0.01% | 5395 |
|
|
2013
Q2 | $4K | Buy |
+2,255
| New | +$4.98K | ﹤0.01% | 5264 |
|
Other funds holding ENZ
RC
XT
KCM
GSC
Wells Fargo's ENZ Position: Q2 2025 in Review
Wells Fargo sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 793 shares — an estimated $294 sold.
Wells Fargo first reported a position in ENZ in Q2 2013 and held it in 48 quarters. The position peaked at $3.16M in Q3 2017. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.
- Wells Fargo reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
- Wells Fargo sold 793 Enzo Biochem, Inc. shares in Q2 2025, an estimated $294.
- Wells Fargo first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 48 quarters.
- Wells Fargo's Enzo Biochem, Inc. position peaked at $3.16M in Q3 2017.
- 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.
Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.